Madopar (Benserazide, Levodopa)

Madopar is an antiparkinson medication that acts on dopaminergic pathways to alleviate motor dysfunction.

• Parkinson's disease: improves bradykinesia, rigidity, and tremor in patients with idiopathic Parkinson's disease.
• Parkinsonian syndrome: reduces motor symptoms in secondary or atypical parkinsonian disorders responsive to levodopa.
• Resting tremor: diminishes tremor amplitude and frequency associated with levodopa‑responsive conditions.

• Levodopa crosses the blood‑brain barrier and is decarboxylated to dopamine, replenishing depleted central dopamine stores. Benserazide, a peripheral dopa‑decaboxylase inhibitor, prevents conversion of levodopa to dopamine outside the brain, increasing the amount of levodopa that reaches the central nervous system and reducing peripheral side effects such as nausea and hypotension.

Common Side Effects

• Nausea or vomiting
• Orthostatic hypotension
• Dyskinesia (involuntary movements)
• Drowsiness or fatigue
• Dry mouth
• Loss of appetite

Serious or Rare Side Effects

• Severe hypertension or hypertensive crisis
• Neuroleptic malignant syndrome when combined with dopamine antagonists
• Cardiac arrhythmias
• Severe psychiatric disturbances (hallucinations, psychosis)
• Allergic reactions (rash, angioedema)

Madopar should be used with caution in specific clinical situations.

• Monitor blood pressure: watch for orthostatic hypotension, especially during dose titration.
• Adjust dose gradually: avoid abrupt discontinuation to prevent withdrawal symptoms.
• Assess hepatic function: use caution in patients with liver impairment.
• Use carefully in the elderly: increased susceptibility to dizziness and falls.
• Avoid concomitant non‑selective MAO inhibitors: risk of hypertensive crisis.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Madopar may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors (e.g., phenelzine): can cause hypertensive crisis.
• Dopamine antagonists (e.g., typical antipsychotics): may reduce therapeutic effect and precipitate severe reactions.
• High‑dose pyridoxine (vitamin B6): accelerates peripheral decarboxylation of levodopa.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: additive blood‑pressure lowering effect.
• Selective serotonin reuptake inhibitors (SSRIs): may increase risk of serotonin syndrome.
• Iron or calcium supplements: may reduce levodopa absorption; separate administration by at least 2 hours.
• Anticholinergic drugs: may mask some motor side effects but increase confusion in the elderly.